RE:RE:Let's be more balanced and positive "And AEZS trades at a discount to its cash for a reason (how about almost 99% shareholder value destruction over the past 20 years, and 4 rollbacks in the last 10 or less years)."
We've been in the worst biotech bear market in history with many early-stage biotech companies trading below cash. That Ciao doesn't know that speaks to his ignorance. In a high inflation environment the market has been very adverse to waiting for profits 5-10 years in the future with a burn rate to get there. The question now is has the inflationary period ended and are early-stage biotech assets a material bargain.
"The combination is attractive for shareholders of both companies, as it is expected to create a long-term sustainable business, which is optimally positioned to deliver value as the biopharma sector recovers from its current levels." news release
AEZS has also been grooming a portfolio of preclinical assets in recent years as it completes the pediatric clinical trial for its diagnostic. The portolio has been groomed to human trial decisions which is where value can accelerate. The pediatric clinical trial for the diagnostic test was expected to be fully enrolled at the end of 2023. Its time for the diagnostic to make money. The pediatric market is the most important market for this test. The market has also had to have the patience to wait and see the diagnostic deal; but has lost patience. Timelines can be extended and AEZS ran into trial delayes because of COVID and Putin's invation of Ukraine. The trial was to, in part, take place in Russia.
Ciao, "Gilles has not partnered with anyone for the last 10 years to advance PGX..."
More nonsense from Ciao. PGX has essentially been partnered with McMaster and the University of Alberta. They discovered PGX-YBG, etc. The Canadian government has funded significant research over time. Recently CZO has signed a deal with industry leader Natex to help advance scale-up. PGX could be at the point of decision for mass industrialization this year which is where partnering can be optimal with commercial partners.
Ciao, "nor brought any new products to the market."
Giant Symrise has applauded its product development partnership with CZO. Numerous applications have been developed over time.
“Ceapro and Symrise have a long-standing relationship in product development that has benefitted both companies over the years,” added Timothy Kenny, Global President Cosmetic Ingredients, Symrise AG." news release
Ciao, "If you've followed the company over the past say 7 years, you will know what failure is."
CZO has attracted significant capital from the Canadian government to support its development. Symrise has applauded its partnership with CZO. Opinion leaders like Dr. Ask, Dr. Hoare, Dr. Kolb, and Dr. Li have applauded CZO's work. CZO has attracted arguably the most important biotech executive in Canada in the last 20 years, Ronnie Miller, and he has applauded CZO's efforts.
Mr. Miller commented, “It is my great pleasure to join the Ceapro Board of Directors at this important time as the Company expands its natural ingredient product expertise into additional potential therapeutic indications. To-date the board and management team have built a solid foundation by putting all the pieces in place for long-term growth. As the Company continues to progress, I look forward to actively working alongside the team to maximize the potential and value of Ceapro.”
Gilles is so excited he wants the next events on NASDAQ and with AEZS he will have the capital to execute his plan for significant growth.
The path,
the daisy chain of events that will define this merger...
AEZS's diagnostic test clinical trial results for children
Launch of powder formulations of CZO's two active ingredients(beta glucan, avenanthramide)
CZO's main client returns
AEZS's diagnostic continuing roll-out for adults
FDA approval for the test for children
Licensing deal for the diagnostic test for North America
Commissioning of 5X PGX scale-up
Commissioning of 10X scale-up to decision point for mass industrialization of PGX
PGX licensing deal
Immune booster plant
Phase I avenanthramide clinical trial results
Wound healing results
Wound healing partnership
Fibrosis clinical trial 'go'/'no go' decision and regulatory filing
Phase IIa avenanthramide clinical trial results
Avenanthramide pill partnership
AIM Biologicals 'go'/'no go' clinical trial decision